Jazz Pharmaceuticals

Jazz Pharmaceuticals is a global biopharmaceutical company based in Dublin, Ireland, focused on developing, acquiring, and commercializing innovative therapies for neuroscience and oncology. The company primarily addresses significant unmet medical needs in areas like narcolepsy, sleep disorders, and various cancers, having successfully brought over 11 therapeutics to market. Operating as a publicly traded entity on NASDAQ, Jazz Pharmaceuticals employs approximately 3,000 individuals globally. Its portfolio expansion includes strategic acquisitions such as GW Pharmaceuticals in 2021, Celator Pharmaceuticals in 2016, and Orphan Medical in 2005, alongside recent licensing agreements like the 2023 deal with Zymeworks for zanidatamab and the Redx Pharma KRAS Inhibitor Program. Bruce C. Cozadd, who serves as Chairman and CEO, co-founded Jazz Pharmaceuticals on March 5, 2003.